Global Alzheimer Disease Treatment Market
Global Alzheimer Disease Treatment Market

Alzheimer Disease Treatment Comprehensive Study by Medications (Cholinesterase Inhibitors, Memantine (Namenda), Other), Diagnose (Blood And Urine Tests, Mental Status Testing, Neuropsychological Testing, Spinal Tap, Brain Imaging Tests), Symptoms (Memory Loss, Language Problems, Cognitive Deficits) Players and Region - Global Market Outlook to 2027

Alzheimer Disease Treatment Market Segmented into XX Submarkets. | Forecast Years: 2022- 2027 | CAGR: 5.8%  

May 2022 Edition 162 Pages 219 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Alzheimer Disease Treatment?
Alzheimer's disease is a chronic neurologic problem that occurs the brain to shrink as well as brain cells to die. Alzheimer's disease is the main cause of dementia, which is defined as a progressive decline in thinking, behavioural, and social skills that impairs a person's ability to function separately. Medications may temporarily improve or slow the progression of signs. These treatments can sometimes help patients with Alzheimer's disease maximise function and maintain independence for a short period of time. Various programmes and services can assist individuals with Alzheimer's disease and their caregivers. There is no treatment that heals Alzheimer's disease or alters the disease process in the brain. Issues from severe loss of brain function, including such dehydration, malnutrition, or infection, result in death in the advanced stages of the disease.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Billion)
Key Companies ProfiledGlaxoSmithKline (GSK) (United Kingdom), Sanofi (France), Eli Lilly (United States), Allergan (Ireland), Eisai Co. Ltd. (Japan), Merck (United States), Novartis AG (Switzerland), Pfizer Inc. (United States), Cipla (India) and AstraZeneca (United Kingdom)
CAGR5.8%


The market study is broken down and major geographies with country level break-up. According to AMA, the Global Alzheimer Disease Treatment market is expected to see growth rate of 5.8% and may see market size of USD6.6 Billion by 2027.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analysts at AMA Research estimates that Players from United States will contribute to the maximum growth of Global Alzheimer Disease Treatment market throughout the predicted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

GlaxoSmithKline (GSK) (United Kingdom), Sanofi (France), Eli Lilly (United States), Allergan (Ireland), Eisai Co. Ltd. (Japan), Merck (United States), Novartis AG (Switzerland), Pfizer Inc. (United States), Cipla (India) and AstraZeneca (United Kingdom) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Sun Pharma (India) and Divi's Laboratories (India).

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Alzheimer Disease Treatment market by Type, Application and Region.

On the basis of geography, the market of Alzheimer Disease Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Medications, the sub-segment i.e. Cholinesterase Inhibitors will boost the Alzheimer Disease Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Diagnose, the sub-segment i.e. Blood And Urine Tests will boost the Alzheimer Disease Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Symptoms, the sub-segment i.e. Memory Loss will boost the Alzheimer Disease Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Leaders and their expansionary development strategies
On 13 April 2022, GlaxoSmithKline plc. and Sierra Oncology, Inc. announced that the companies have entered into an agreement under which GSK will acquire Sierra Oncology, a California-based, late-stage biopharmaceutical company focused on targeted therapies for the treatment of rare forms of cancer,
U.S. Food and Drug Administration approved Aduhelm (aducanumab) for the treatment of Alzheimer’s, a debilitating. Aduhelm was approved using the accelerated approval pathway, which can be used for a drug for a serious or life-threatening illness that provides a meaningful therapeutic advantage over existing treatments.


Market Trend
  • Rapid Development in Alzheimer Disease Treatment

Market Drivers
  • High Growth in Healthcare Spending and Improvements in Healthcare Infrastructure
  • High Growth in Geriatric Population

Opportunities
  • High Growth In Healthcare Expenditure
  • The Rise In The Investment In Research And Development By Public And Private Hospitals

Restraints
  • Lack Of Proper Awareness In Under Developing Regions
  • Side Effects Associated With These Treatment

Challenges
  • The Less Number Of Available Treatments
  • High-Cost Associated Of Alzheimer Disease Treatment


Key Target Audience
Alzheimer Disease Treatment, New Entrants and Investors, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Frequently Asked Questions (FAQ):

1. What all players are profiled in the study?
The standard version of the report profiles players such as GlaxoSmithKline (GSK) (United Kingdom), Sanofi (France), Eli Lilly (United States), Allergan (Ireland), Eisai Co. Ltd. (Japan), Merck (United States), Novartis AG (Switzerland), Pfizer Inc. (United States), Cipla (India) and AstraZeneca (United Kingdom) etc.

2. Can we have customized study for Alzheimer Disease Treatment Market?
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

3. What would be the Market Size of Alzheimer Disease Treatment Market by 2027?
Analysts at AMA estimates Alzheimer Disease Treatment Market to reach USD6.6 Billion by 2027.
Report Objectives / Segmentation Covered
By Medications
  • Cholinesterase Inhibitors
  • Memantine (Namenda)
  • Other

By Diagnose
  • Blood And Urine Tests
  • Mental Status Testing
  • Neuropsychological Testing
  • Spinal Tap
  • Brain Imaging Tests

By Symptoms
  • Memory Loss
  • Language Problems
  • Cognitive Deficits

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. High Growth in Healthcare Spending and Improvements in Healthcare Infrastructure
      • 3.2.2. High Growth in Geriatric Population
    • 3.3. Market Challenges
      • 3.3.1. The Less Number Of Available Treatments
      • 3.3.2. High-Cost Associated Of Alzheimer Disease Treatment
    • 3.4. Market Trends
      • 3.4.1. Rapid Development in Alzheimer Disease Treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Alzheimer Disease Treatment, by Medications, Diagnose, Symptoms and Region (value) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Alzheimer Disease Treatment (Value)
      • 5.2.1. Global Alzheimer Disease Treatment by: Medications (Value)
        • 5.2.1.1. Cholinesterase Inhibitors
        • 5.2.1.2. Memantine (Namenda)
        • 5.2.1.3. Other
      • 5.2.2. Global Alzheimer Disease Treatment by: Diagnose (Value)
        • 5.2.2.1. Blood And Urine Tests
        • 5.2.2.2. Mental Status Testing
        • 5.2.2.3. Neuropsychological Testing
        • 5.2.2.4. Spinal Tap
        • 5.2.2.5. Brain Imaging Tests
      • 5.2.3. Global Alzheimer Disease Treatment by: Symptoms (Value)
        • 5.2.3.1. Memory Loss
        • 5.2.3.2. Language Problems
        • 5.2.3.3. Cognitive Deficits
      • 5.2.4. Global Alzheimer Disease Treatment Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Australia
          • 5.2.4.2.6. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Alzheimer Disease Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline (GSK) (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Sanofi (France)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Eli Lilly (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Allergan (Ireland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Eisai Co. Ltd. (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Merck (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Novartis AG (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Pfizer Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Cipla (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. AstraZeneca (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Alzheimer Disease Treatment Sale, by Medications, Diagnose, Symptoms and Region (value) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Alzheimer Disease Treatment (Value)
      • 7.2.1. Global Alzheimer Disease Treatment by: Medications (Value)
        • 7.2.1.1. Cholinesterase Inhibitors
        • 7.2.1.2. Memantine (Namenda)
        • 7.2.1.3. Other
      • 7.2.2. Global Alzheimer Disease Treatment by: Diagnose (Value)
        • 7.2.2.1. Blood And Urine Tests
        • 7.2.2.2. Mental Status Testing
        • 7.2.2.3. Neuropsychological Testing
        • 7.2.2.4. Spinal Tap
        • 7.2.2.5. Brain Imaging Tests
      • 7.2.3. Global Alzheimer Disease Treatment by: Symptoms (Value)
        • 7.2.3.1. Memory Loss
        • 7.2.3.2. Language Problems
        • 7.2.3.3. Cognitive Deficits
      • 7.2.4. Global Alzheimer Disease Treatment Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Australia
          • 7.2.4.2.6. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Alzheimer Disease Treatment: by Medications(USD Billion)
  • Table 2. Alzheimer Disease Treatment Cholinesterase Inhibitors , by Region USD Billion (2016-2021)
  • Table 3. Alzheimer Disease Treatment Memantine (Namenda) , by Region USD Billion (2016-2021)
  • Table 4. Alzheimer Disease Treatment Other , by Region USD Billion (2016-2021)
  • Table 5. Alzheimer Disease Treatment: by Diagnose(USD Billion)
  • Table 6. Alzheimer Disease Treatment Blood And Urine Tests , by Region USD Billion (2016-2021)
  • Table 7. Alzheimer Disease Treatment Mental Status Testing , by Region USD Billion (2016-2021)
  • Table 8. Alzheimer Disease Treatment Neuropsychological Testing , by Region USD Billion (2016-2021)
  • Table 9. Alzheimer Disease Treatment Spinal Tap , by Region USD Billion (2016-2021)
  • Table 10. Alzheimer Disease Treatment Brain Imaging Tests , by Region USD Billion (2016-2021)
  • Table 11. Alzheimer Disease Treatment: by Symptoms(USD Billion)
  • Table 12. Alzheimer Disease Treatment Memory Loss , by Region USD Billion (2016-2021)
  • Table 13. Alzheimer Disease Treatment Language Problems , by Region USD Billion (2016-2021)
  • Table 14. Alzheimer Disease Treatment Cognitive Deficits , by Region USD Billion (2016-2021)
  • Table 15. South America Alzheimer Disease Treatment, by Country USD Billion (2016-2021)
  • Table 16. South America Alzheimer Disease Treatment, by Medications USD Billion (2016-2021)
  • Table 17. South America Alzheimer Disease Treatment, by Diagnose USD Billion (2016-2021)
  • Table 18. South America Alzheimer Disease Treatment, by Symptoms USD Billion (2016-2021)
  • Table 19. Brazil Alzheimer Disease Treatment, by Medications USD Billion (2016-2021)
  • Table 20. Brazil Alzheimer Disease Treatment, by Diagnose USD Billion (2016-2021)
  • Table 21. Brazil Alzheimer Disease Treatment, by Symptoms USD Billion (2016-2021)
  • Table 22. Argentina Alzheimer Disease Treatment, by Medications USD Billion (2016-2021)
  • Table 23. Argentina Alzheimer Disease Treatment, by Diagnose USD Billion (2016-2021)
  • Table 24. Argentina Alzheimer Disease Treatment, by Symptoms USD Billion (2016-2021)
  • Table 25. Rest of South America Alzheimer Disease Treatment, by Medications USD Billion (2016-2021)
  • Table 26. Rest of South America Alzheimer Disease Treatment, by Diagnose USD Billion (2016-2021)
  • Table 27. Rest of South America Alzheimer Disease Treatment, by Symptoms USD Billion (2016-2021)
  • Table 28. Asia Pacific Alzheimer Disease Treatment, by Country USD Billion (2016-2021)
  • Table 29. Asia Pacific Alzheimer Disease Treatment, by Medications USD Billion (2016-2021)
  • Table 30. Asia Pacific Alzheimer Disease Treatment, by Diagnose USD Billion (2016-2021)
  • Table 31. Asia Pacific Alzheimer Disease Treatment, by Symptoms USD Billion (2016-2021)
  • Table 32. China Alzheimer Disease Treatment, by Medications USD Billion (2016-2021)
  • Table 33. China Alzheimer Disease Treatment, by Diagnose USD Billion (2016-2021)
  • Table 34. China Alzheimer Disease Treatment, by Symptoms USD Billion (2016-2021)
  • Table 35. Japan Alzheimer Disease Treatment, by Medications USD Billion (2016-2021)
  • Table 36. Japan Alzheimer Disease Treatment, by Diagnose USD Billion (2016-2021)
  • Table 37. Japan Alzheimer Disease Treatment, by Symptoms USD Billion (2016-2021)
  • Table 38. India Alzheimer Disease Treatment, by Medications USD Billion (2016-2021)
  • Table 39. India Alzheimer Disease Treatment, by Diagnose USD Billion (2016-2021)
  • Table 40. India Alzheimer Disease Treatment, by Symptoms USD Billion (2016-2021)
  • Table 41. South Korea Alzheimer Disease Treatment, by Medications USD Billion (2016-2021)
  • Table 42. South Korea Alzheimer Disease Treatment, by Diagnose USD Billion (2016-2021)
  • Table 43. South Korea Alzheimer Disease Treatment, by Symptoms USD Billion (2016-2021)
  • Table 44. Australia Alzheimer Disease Treatment, by Medications USD Billion (2016-2021)
  • Table 45. Australia Alzheimer Disease Treatment, by Diagnose USD Billion (2016-2021)
  • Table 46. Australia Alzheimer Disease Treatment, by Symptoms USD Billion (2016-2021)
  • Table 47. Rest of Asia-Pacific Alzheimer Disease Treatment, by Medications USD Billion (2016-2021)
  • Table 48. Rest of Asia-Pacific Alzheimer Disease Treatment, by Diagnose USD Billion (2016-2021)
  • Table 49. Rest of Asia-Pacific Alzheimer Disease Treatment, by Symptoms USD Billion (2016-2021)
  • Table 50. Europe Alzheimer Disease Treatment, by Country USD Billion (2016-2021)
  • Table 51. Europe Alzheimer Disease Treatment, by Medications USD Billion (2016-2021)
  • Table 52. Europe Alzheimer Disease Treatment, by Diagnose USD Billion (2016-2021)
  • Table 53. Europe Alzheimer Disease Treatment, by Symptoms USD Billion (2016-2021)
  • Table 54. Germany Alzheimer Disease Treatment, by Medications USD Billion (2016-2021)
  • Table 55. Germany Alzheimer Disease Treatment, by Diagnose USD Billion (2016-2021)
  • Table 56. Germany Alzheimer Disease Treatment, by Symptoms USD Billion (2016-2021)
  • Table 57. France Alzheimer Disease Treatment, by Medications USD Billion (2016-2021)
  • Table 58. France Alzheimer Disease Treatment, by Diagnose USD Billion (2016-2021)
  • Table 59. France Alzheimer Disease Treatment, by Symptoms USD Billion (2016-2021)
  • Table 60. Italy Alzheimer Disease Treatment, by Medications USD Billion (2016-2021)
  • Table 61. Italy Alzheimer Disease Treatment, by Diagnose USD Billion (2016-2021)
  • Table 62. Italy Alzheimer Disease Treatment, by Symptoms USD Billion (2016-2021)
  • Table 63. United Kingdom Alzheimer Disease Treatment, by Medications USD Billion (2016-2021)
  • Table 64. United Kingdom Alzheimer Disease Treatment, by Diagnose USD Billion (2016-2021)
  • Table 65. United Kingdom Alzheimer Disease Treatment, by Symptoms USD Billion (2016-2021)
  • Table 66. Netherlands Alzheimer Disease Treatment, by Medications USD Billion (2016-2021)
  • Table 67. Netherlands Alzheimer Disease Treatment, by Diagnose USD Billion (2016-2021)
  • Table 68. Netherlands Alzheimer Disease Treatment, by Symptoms USD Billion (2016-2021)
  • Table 69. Rest of Europe Alzheimer Disease Treatment, by Medications USD Billion (2016-2021)
  • Table 70. Rest of Europe Alzheimer Disease Treatment, by Diagnose USD Billion (2016-2021)
  • Table 71. Rest of Europe Alzheimer Disease Treatment, by Symptoms USD Billion (2016-2021)
  • Table 72. MEA Alzheimer Disease Treatment, by Country USD Billion (2016-2021)
  • Table 73. MEA Alzheimer Disease Treatment, by Medications USD Billion (2016-2021)
  • Table 74. MEA Alzheimer Disease Treatment, by Diagnose USD Billion (2016-2021)
  • Table 75. MEA Alzheimer Disease Treatment, by Symptoms USD Billion (2016-2021)
  • Table 76. Middle East Alzheimer Disease Treatment, by Medications USD Billion (2016-2021)
  • Table 77. Middle East Alzheimer Disease Treatment, by Diagnose USD Billion (2016-2021)
  • Table 78. Middle East Alzheimer Disease Treatment, by Symptoms USD Billion (2016-2021)
  • Table 79. Africa Alzheimer Disease Treatment, by Medications USD Billion (2016-2021)
  • Table 80. Africa Alzheimer Disease Treatment, by Diagnose USD Billion (2016-2021)
  • Table 81. Africa Alzheimer Disease Treatment, by Symptoms USD Billion (2016-2021)
  • Table 82. North America Alzheimer Disease Treatment, by Country USD Billion (2016-2021)
  • Table 83. North America Alzheimer Disease Treatment, by Medications USD Billion (2016-2021)
  • Table 84. North America Alzheimer Disease Treatment, by Diagnose USD Billion (2016-2021)
  • Table 85. North America Alzheimer Disease Treatment, by Symptoms USD Billion (2016-2021)
  • Table 86. United States Alzheimer Disease Treatment, by Medications USD Billion (2016-2021)
  • Table 87. United States Alzheimer Disease Treatment, by Diagnose USD Billion (2016-2021)
  • Table 88. United States Alzheimer Disease Treatment, by Symptoms USD Billion (2016-2021)
  • Table 89. Canada Alzheimer Disease Treatment, by Medications USD Billion (2016-2021)
  • Table 90. Canada Alzheimer Disease Treatment, by Diagnose USD Billion (2016-2021)
  • Table 91. Canada Alzheimer Disease Treatment, by Symptoms USD Billion (2016-2021)
  • Table 92. Mexico Alzheimer Disease Treatment, by Medications USD Billion (2016-2021)
  • Table 93. Mexico Alzheimer Disease Treatment, by Diagnose USD Billion (2016-2021)
  • Table 94. Mexico Alzheimer Disease Treatment, by Symptoms USD Billion (2016-2021)
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Alzheimer Disease Treatment: by Medications(USD Billion)
  • Table 106. Alzheimer Disease Treatment Cholinesterase Inhibitors , by Region USD Billion (2022-2027)
  • Table 107. Alzheimer Disease Treatment Memantine (Namenda) , by Region USD Billion (2022-2027)
  • Table 108. Alzheimer Disease Treatment Other , by Region USD Billion (2022-2027)
  • Table 109. Alzheimer Disease Treatment: by Diagnose(USD Billion)
  • Table 110. Alzheimer Disease Treatment Blood And Urine Tests , by Region USD Billion (2022-2027)
  • Table 111. Alzheimer Disease Treatment Mental Status Testing , by Region USD Billion (2022-2027)
  • Table 112. Alzheimer Disease Treatment Neuropsychological Testing , by Region USD Billion (2022-2027)
  • Table 113. Alzheimer Disease Treatment Spinal Tap , by Region USD Billion (2022-2027)
  • Table 114. Alzheimer Disease Treatment Brain Imaging Tests , by Region USD Billion (2022-2027)
  • Table 115. Alzheimer Disease Treatment: by Symptoms(USD Billion)
  • Table 116. Alzheimer Disease Treatment Memory Loss , by Region USD Billion (2022-2027)
  • Table 117. Alzheimer Disease Treatment Language Problems , by Region USD Billion (2022-2027)
  • Table 118. Alzheimer Disease Treatment Cognitive Deficits , by Region USD Billion (2022-2027)
  • Table 119. South America Alzheimer Disease Treatment, by Country USD Billion (2022-2027)
  • Table 120. South America Alzheimer Disease Treatment, by Medications USD Billion (2022-2027)
  • Table 121. South America Alzheimer Disease Treatment, by Diagnose USD Billion (2022-2027)
  • Table 122. South America Alzheimer Disease Treatment, by Symptoms USD Billion (2022-2027)
  • Table 123. Brazil Alzheimer Disease Treatment, by Medications USD Billion (2022-2027)
  • Table 124. Brazil Alzheimer Disease Treatment, by Diagnose USD Billion (2022-2027)
  • Table 125. Brazil Alzheimer Disease Treatment, by Symptoms USD Billion (2022-2027)
  • Table 126. Argentina Alzheimer Disease Treatment, by Medications USD Billion (2022-2027)
  • Table 127. Argentina Alzheimer Disease Treatment, by Diagnose USD Billion (2022-2027)
  • Table 128. Argentina Alzheimer Disease Treatment, by Symptoms USD Billion (2022-2027)
  • Table 129. Rest of South America Alzheimer Disease Treatment, by Medications USD Billion (2022-2027)
  • Table 130. Rest of South America Alzheimer Disease Treatment, by Diagnose USD Billion (2022-2027)
  • Table 131. Rest of South America Alzheimer Disease Treatment, by Symptoms USD Billion (2022-2027)
  • Table 132. Asia Pacific Alzheimer Disease Treatment, by Country USD Billion (2022-2027)
  • Table 133. Asia Pacific Alzheimer Disease Treatment, by Medications USD Billion (2022-2027)
  • Table 134. Asia Pacific Alzheimer Disease Treatment, by Diagnose USD Billion (2022-2027)
  • Table 135. Asia Pacific Alzheimer Disease Treatment, by Symptoms USD Billion (2022-2027)
  • Table 136. China Alzheimer Disease Treatment, by Medications USD Billion (2022-2027)
  • Table 137. China Alzheimer Disease Treatment, by Diagnose USD Billion (2022-2027)
  • Table 138. China Alzheimer Disease Treatment, by Symptoms USD Billion (2022-2027)
  • Table 139. Japan Alzheimer Disease Treatment, by Medications USD Billion (2022-2027)
  • Table 140. Japan Alzheimer Disease Treatment, by Diagnose USD Billion (2022-2027)
  • Table 141. Japan Alzheimer Disease Treatment, by Symptoms USD Billion (2022-2027)
  • Table 142. India Alzheimer Disease Treatment, by Medications USD Billion (2022-2027)
  • Table 143. India Alzheimer Disease Treatment, by Diagnose USD Billion (2022-2027)
  • Table 144. India Alzheimer Disease Treatment, by Symptoms USD Billion (2022-2027)
  • Table 145. South Korea Alzheimer Disease Treatment, by Medications USD Billion (2022-2027)
  • Table 146. South Korea Alzheimer Disease Treatment, by Diagnose USD Billion (2022-2027)
  • Table 147. South Korea Alzheimer Disease Treatment, by Symptoms USD Billion (2022-2027)
  • Table 148. Australia Alzheimer Disease Treatment, by Medications USD Billion (2022-2027)
  • Table 149. Australia Alzheimer Disease Treatment, by Diagnose USD Billion (2022-2027)
  • Table 150. Australia Alzheimer Disease Treatment, by Symptoms USD Billion (2022-2027)
  • Table 151. Rest of Asia-Pacific Alzheimer Disease Treatment, by Medications USD Billion (2022-2027)
  • Table 152. Rest of Asia-Pacific Alzheimer Disease Treatment, by Diagnose USD Billion (2022-2027)
  • Table 153. Rest of Asia-Pacific Alzheimer Disease Treatment, by Symptoms USD Billion (2022-2027)
  • Table 154. Europe Alzheimer Disease Treatment, by Country USD Billion (2022-2027)
  • Table 155. Europe Alzheimer Disease Treatment, by Medications USD Billion (2022-2027)
  • Table 156. Europe Alzheimer Disease Treatment, by Diagnose USD Billion (2022-2027)
  • Table 157. Europe Alzheimer Disease Treatment, by Symptoms USD Billion (2022-2027)
  • Table 158. Germany Alzheimer Disease Treatment, by Medications USD Billion (2022-2027)
  • Table 159. Germany Alzheimer Disease Treatment, by Diagnose USD Billion (2022-2027)
  • Table 160. Germany Alzheimer Disease Treatment, by Symptoms USD Billion (2022-2027)
  • Table 161. France Alzheimer Disease Treatment, by Medications USD Billion (2022-2027)
  • Table 162. France Alzheimer Disease Treatment, by Diagnose USD Billion (2022-2027)
  • Table 163. France Alzheimer Disease Treatment, by Symptoms USD Billion (2022-2027)
  • Table 164. Italy Alzheimer Disease Treatment, by Medications USD Billion (2022-2027)
  • Table 165. Italy Alzheimer Disease Treatment, by Diagnose USD Billion (2022-2027)
  • Table 166. Italy Alzheimer Disease Treatment, by Symptoms USD Billion (2022-2027)
  • Table 167. United Kingdom Alzheimer Disease Treatment, by Medications USD Billion (2022-2027)
  • Table 168. United Kingdom Alzheimer Disease Treatment, by Diagnose USD Billion (2022-2027)
  • Table 169. United Kingdom Alzheimer Disease Treatment, by Symptoms USD Billion (2022-2027)
  • Table 170. Netherlands Alzheimer Disease Treatment, by Medications USD Billion (2022-2027)
  • Table 171. Netherlands Alzheimer Disease Treatment, by Diagnose USD Billion (2022-2027)
  • Table 172. Netherlands Alzheimer Disease Treatment, by Symptoms USD Billion (2022-2027)
  • Table 173. Rest of Europe Alzheimer Disease Treatment, by Medications USD Billion (2022-2027)
  • Table 174. Rest of Europe Alzheimer Disease Treatment, by Diagnose USD Billion (2022-2027)
  • Table 175. Rest of Europe Alzheimer Disease Treatment, by Symptoms USD Billion (2022-2027)
  • Table 176. MEA Alzheimer Disease Treatment, by Country USD Billion (2022-2027)
  • Table 177. MEA Alzheimer Disease Treatment, by Medications USD Billion (2022-2027)
  • Table 178. MEA Alzheimer Disease Treatment, by Diagnose USD Billion (2022-2027)
  • Table 179. MEA Alzheimer Disease Treatment, by Symptoms USD Billion (2022-2027)
  • Table 180. Middle East Alzheimer Disease Treatment, by Medications USD Billion (2022-2027)
  • Table 181. Middle East Alzheimer Disease Treatment, by Diagnose USD Billion (2022-2027)
  • Table 182. Middle East Alzheimer Disease Treatment, by Symptoms USD Billion (2022-2027)
  • Table 183. Africa Alzheimer Disease Treatment, by Medications USD Billion (2022-2027)
  • Table 184. Africa Alzheimer Disease Treatment, by Diagnose USD Billion (2022-2027)
  • Table 185. Africa Alzheimer Disease Treatment, by Symptoms USD Billion (2022-2027)
  • Table 186. North America Alzheimer Disease Treatment, by Country USD Billion (2022-2027)
  • Table 187. North America Alzheimer Disease Treatment, by Medications USD Billion (2022-2027)
  • Table 188. North America Alzheimer Disease Treatment, by Diagnose USD Billion (2022-2027)
  • Table 189. North America Alzheimer Disease Treatment, by Symptoms USD Billion (2022-2027)
  • Table 190. United States Alzheimer Disease Treatment, by Medications USD Billion (2022-2027)
  • Table 191. United States Alzheimer Disease Treatment, by Diagnose USD Billion (2022-2027)
  • Table 192. United States Alzheimer Disease Treatment, by Symptoms USD Billion (2022-2027)
  • Table 193. Canada Alzheimer Disease Treatment, by Medications USD Billion (2022-2027)
  • Table 194. Canada Alzheimer Disease Treatment, by Diagnose USD Billion (2022-2027)
  • Table 195. Canada Alzheimer Disease Treatment, by Symptoms USD Billion (2022-2027)
  • Table 196. Mexico Alzheimer Disease Treatment, by Medications USD Billion (2022-2027)
  • Table 197. Mexico Alzheimer Disease Treatment, by Diagnose USD Billion (2022-2027)
  • Table 198. Mexico Alzheimer Disease Treatment, by Symptoms USD Billion (2022-2027)
  • Table 199. Research Programs/Design for This Report
  • Table 200. Key Data Information from Secondary Sources
  • Table 201. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Alzheimer Disease Treatment: by Medications USD Billion (2016-2021)
  • Figure 5. Global Alzheimer Disease Treatment: by Diagnose USD Billion (2016-2021)
  • Figure 6. Global Alzheimer Disease Treatment: by Symptoms USD Billion (2016-2021)
  • Figure 7. South America Alzheimer Disease Treatment Share (%), by Country
  • Figure 8. Asia Pacific Alzheimer Disease Treatment Share (%), by Country
  • Figure 9. Europe Alzheimer Disease Treatment Share (%), by Country
  • Figure 10. MEA Alzheimer Disease Treatment Share (%), by Country
  • Figure 11. North America Alzheimer Disease Treatment Share (%), by Country
  • Figure 12. Global Alzheimer Disease Treatment share by Players 2021 (%)
  • Figure 13. Global Alzheimer Disease Treatment share by Players (Top 3) 2021(%)
  • Figure 14. Global Alzheimer Disease Treatment share by Players (Top 5) 2021(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. GlaxoSmithKline (GSK) (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 17. GlaxoSmithKline (GSK) (United Kingdom) Revenue: by Geography 2021
  • Figure 18. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 19. Sanofi (France) Revenue: by Geography 2021
  • Figure 20. Eli Lilly (United States) Revenue, Net Income and Gross profit
  • Figure 21. Eli Lilly (United States) Revenue: by Geography 2021
  • Figure 22. Allergan (Ireland) Revenue, Net Income and Gross profit
  • Figure 23. Allergan (Ireland) Revenue: by Geography 2021
  • Figure 24. Eisai Co. Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 25. Eisai Co. Ltd. (Japan) Revenue: by Geography 2021
  • Figure 26. Merck (United States) Revenue, Net Income and Gross profit
  • Figure 27. Merck (United States) Revenue: by Geography 2021
  • Figure 28. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 29. Novartis AG (Switzerland) Revenue: by Geography 2021
  • Figure 30. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Pfizer Inc. (United States) Revenue: by Geography 2021
  • Figure 32. Cipla (India) Revenue, Net Income and Gross profit
  • Figure 33. Cipla (India) Revenue: by Geography 2021
  • Figure 34. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 35. AstraZeneca (United Kingdom) Revenue: by Geography 2021
  • Figure 36. Global Alzheimer Disease Treatment: by Medications USD Billion (2022-2027)
  • Figure 37. Global Alzheimer Disease Treatment: by Diagnose USD Billion (2022-2027)
  • Figure 38. Global Alzheimer Disease Treatment: by Symptoms USD Billion (2022-2027)
  • Figure 39. South America Alzheimer Disease Treatment Share (%), by Country
  • Figure 40. Asia Pacific Alzheimer Disease Treatment Share (%), by Country
  • Figure 41. Europe Alzheimer Disease Treatment Share (%), by Country
  • Figure 42. MEA Alzheimer Disease Treatment Share (%), by Country
  • Figure 43. North America Alzheimer Disease Treatment Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • GlaxoSmithKline (GSK) (United Kingdom)
  • Sanofi (France)
  • Eli Lilly (United States)
  • Allergan (Ireland)
  • Eisai Co. Ltd. (Japan)
  • Merck (United States)
  • Novartis AG (Switzerland)
  • Pfizer Inc. (United States)
  • Cipla (India)
  • AstraZeneca (United Kingdom)
Additional players considered in the study are as follows:
Sun Pharma (India) , Divi's Laboratories (India)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation